PENELOPE-B: Palbociclib Disappoints in HR+, HER2– Breast Cancer ...Middle East

Medscape - News
The CDK4/6 inhibitor palbociclib provides no significant benefit in patients with HR+, HER2-negative primary breast cancer, according to first results from the PENELOPE-B trial. Medscape Medical News

Hence then, the article about penelope b palbociclib disappoints in hr her2 breast cancer was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( PENELOPE-B: Palbociclib Disappoints in HR+, HER2– Breast Cancer )

Apple Storegoogle play

Last updated :

Also on site :